1.08
+1.89%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About MindWalk Holdings
Its shares trade under the ticker HYFT. It has been listed since 30 January 1987. In the fiscal year to 30 April 2026, it reported revenue of C$15.3m and a net loss of C$13.7m. At that date it held total assets of C$21.3m and shareholders' equity of C$11.7m.
ImmunoPrecise Antibodies Ltd. is a therapeutic antibody discovery company, which engages in the provision of human therapeutic antibody discovery and development services. The company is headquartered in Vancouver, British Columbia. The firm offers species-agnostic advancements, such as the B cell Select single-cell interrogation technology, DeepDisplay custom phage libraries, as well as the Abthena bispecific program- platforms. The company leverages systems biology, multi-omics modelling and complex artificial intelligence systems to support its technologies in bio platform-based antibody discovery. The company offers a selection of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma licensing for research purposes. Its services include specialized, full-continuum therapeutic biologics discovery, development, and out-licensing to support its business partners. The firm offers support to its partners, including rapid multi-omic analysis, customized project design, target identification and preparation, an on-site vivarium, and others.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 30 Jan 1987
- Employees
- 85
- Website
- immunoprecise.com ↗
- Head office
- 3204-4464 MARKHAM STREET, VICTORIA
- Incorporated in
- A1
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Dr. Jennifer BathPresident, Chief Executive Officer, Director, since 2018C$1.1m
- Mr. Joseph SchefflerInterim Chief Financial OfficerC$146,929
- Ms. Kari GraberVice President - Commercial ServicesC$331,488
- Dr. Shuji SatoVice President - Innovative SolutionsC$290,052
- Mr. Jonathan LieberDirector
- Dr. Kamil IsaevIndependent Director
- Mr. Dirk WittersIndependent DirectorC$94,619
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- ImmunoPrecise Antibodies Ltd. offers B cell Select single-cell technology for antibody discovery.
- DeepDisplay custom phage libraries support advanced therapeutic development.
- Abthena bispecific program platforms enhance biologics discovery capabilities.
Weaknesses
- ImmunoPrecise employs 85 full-time employees in Vancouver, Canada.
- The company provides antibodies, enzymes, and arthritis animal products for research.
- Vancouver headquarters limits geographic expansion opportunities.
Opportunities
- Life Sciences Tools & Services sector growth in Health Care industry.
- Therapeutic antibody discovery services meet increasing market demand.
- Multi-omics modelling and AI systems drive innovation in bio platforms.
Threats
- Vancouver's location may hinder global market access.
- ImmunoPrecise's small employee count affects scalability.
- Limited product range compared to larger competitors.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.